Condition: Bladder Cancer · Non Muscle Invasive · Sponsor: Zhuhai Beihai Biotech Co., Ltd
The purpose of this study is to determine the safety and tolerability of intravesical BH011 in patients with high-risk non-muscle invasive bladder cancer（NMIBC） after Bacillus Calmette-Guerin（BCG） failure and to assess the preliminary efficacy.
This description comes directly from the study's public registry record.
Xiaohua Wei · +86 756 6349669 · xhwei@bayhibiotech.com
Always discuss trial participation with your own doctor first.
| Peking University First Hospital | Beijing, Beijing Municipality, China | Recruiting |
| The First Affiliated Hospital of Xiamen University | Xiamen, Fujian, China | Completed |
| Hunan Cancer Hospital | Changsha, Hunan, China | Completed |
| Shengjing Hospital of China Medical University | Shenyang, Liaoning, China | Completed |
| Fudan University Shanghai Cancer Center | Shanghai, Shanghai Municipality, China | Recruiting |
| The Second Hospital of Tianjin Medical University | Tianjin, Tianjin Municipality, China | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT06732531